The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shvarts V.Ia.

Reabilitatsionnaia klinika Bad Kolberg, Germaniia

A new principle of the treatment of type 2 diabetes mellitus by stimulation of glucosuria

Authors:

Shvarts V.Ia.

More about the authors

Journal: Problems of Endocrinology. 2012;58(4): 54‑57

Read: 2415 times

Download PDF (RU)
Contact the author
Table of contents

A NEW PRINCIPLE OF THE TREATMENT OF TYPE 2 DIABETES MELLITUS BY STIMULATION OF GLUCOSURIA
A NEW PRINCIPLE OF THE TREATMENT OF TYPE 2 DIABETES MELLITUS BY STIMULATION OF GLUCOSURIA

To cite this article:

Shvarts VIa. A new principle of the treatment of type 2 diabetes mellitus by stimulation of glucosuria. Problems of Endocrinology. 2012;58(4):54‑57. (In Russ.)

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Psoriasis: analysis of como­rbid pathology. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(1):16-21
Cognitive functions asse­ssment of elde­rly patients with type 2 diabetes mellitus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):46-50
Features of comprehensive treatment in a patient with complicated type 2 diabetes mellitus: A clinical case. Piro­gov Russian Journal of Surgery. 2025;(6):128-132
Early diagnosis and effe­ctive therapy of diabetic poly­neuropathy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):62-68
Hype­rtensive diso­rders of pregnancy as a risk factor for chro­nic non-communicable diseases. Russian Journal of Preventive Medi­cine. 2025;(6):114-119
Cere­brovascular disease in clinical practice. Reso­lution of the Expert Council of the Russian Scientific Medi­cal Society of Therapists. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):105-111
Late complications and quality of life after multivisceral surgeries with pancreatoduodenectomy. Piro­gov Russian Journal of Surgery. 2025;(7):36-45
Painful diabetic poly­neuropathy in patients with cere­brovascular diseases. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):64-72
A review of the recent clinical studies on the treatment of patients with the chro­nic kidney disease et adva­nced stages. Russian Journal of Preventive Medi­cine. 2025;(8):110-114
Algo­rithm for the diagnosis and treatment of patients with diabetic poly­neuropathy. Expert Council Reso­lution (March 1, 2025). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):102-113
Abstract:

The results of clinical and experimental studies of a new group of medications are presented, with special emphasis laid on the inhibitors of sodium-glucose co-transporter SGLT2 employed for the treatment of type 2 diabetes mellitus. The mechanism of action of these inhibitors consists of the stimulation of glucosuria and the subsequent decrease of hyperglycemia. The new group of pharmaceutical products being considered is characterized by high therapeutic efficacy, safety, and the narrow spectrum of side effects. The most important adverse reactions are infectious lesions in the urinary tract and genital organs.

Keywords:

diabetes mellitus
glucose reabsorption
SGLT2 inhibitors
dapagliflozi

Authors:

Shvarts V.Ia.

Reabilitatsionnaia klinika Bad Kolberg, Germaniia

Close metadata

References:

  1. Bakris G.L., Fonseca V.A., Sharma K., Wright E.M. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009; 75: 1272-1277.
  2. Zelikovic I. Aminoaciduria and glycosuria. In: Pediatric Nephrology. Eds. E.D. Avner, W.E. Harmon, P. Niaudet. 5th edition. Philadelphia: Lippincott Williams & Wilkins 2004; 701-728.
  3. Moe O.W., Wright S.H., Palacín M. Renal handling of organic solutes. In: Brenner and Rector's The Kidney. Ed. B.M. Brenner. 8th edition. Philadelphia: Saunders Elsevier 2008; 214-247.
  4. Hediger M.A., Coady M.J., Ikeda T.S., Wright E.M. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature 1987; 330: 379-381.
  5. Wright E.M., Hirayama B.A., Loo D.F. Active sugar transport in health and disease. J Intern Med 2007; 261: 32-43.
  6. Ehrenkranz R.R.L., Lewis N.G., Kahn C.R., Roth J. Phlorizin: a review. Diabet Metab Res Rev 2005; 21: 31-38.
  7. Washburn W.N. Evolution of sodium glucose cotransporter 2 inhibitors as anti-diabetic agents. Exp Opin Ther Patents 2009; 19: 1485-1499.
  8. Fujimoto Y., Torres T.P., Donahue E.P., Shiota M. Glucose toxicity is responsible for the development of impaired regulation of endogenous glucose production and hepatic glucokinase in Zucker diabetic fatty rats. Diabetes 2006; 55: 2479-2490.
  9. Abdul-Ghani M.A., Norton L., Defronzo R.A. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocrinol Rev 2011; 32: 4: 515-531.
  10. Washburn W.N. Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. J Med Chem 2009; 52: 1785-1794.
  11. Bailey C.J., Gross J.L., Pieters A., Bastien A., List J. Effect of dapagliflozin in patienzs with type 2 diabetes who have inadequate glyceamic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-2233.
  12. Nauck M.A., Del Prato S., Meier J.J., Durán-García S., Rohwedder K., Elze M., Parikh S.J. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequete glyceamic control with metformin: a randomised, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 2011; 34: 2015-2022.
  13. Kasichayanula S., Liu X., Shyu W.C., Zhang W., Pfister M., Griffen S.G., Li T., LaGreta F.P., Boulton D.W. Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimeperide or sitagliptin in healthy subjects. Diabetes Obes Metab 2011; 13: 47-54.
  14. Zhang L., Feng Y., List J., Pfister M., Ng C.M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effect on glycaemic control and body weight. Diabetes Obes Metab 2010; 12: 510-516.
  15. Komoroski B., Vachharajani N., Feng Y., Li L., Kornhauser D., Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharm Ther 2009; 85: 513-519.
  16. Ng C.M., Zhang L., List J., Pfister M. Mechanismbased disease model to describe the plasma/urine glucose-time profiles in placebo-or dapagliflozin-treated normal and type 2 diabetes mellitus (T2DM) subjects. Clin Pharm Ther 2010; 87: Suppl 1: S17-S18.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.